HONEYWELL AND RECIPHARM TO SPEED DEVELOPMENT OF INHALERS WITH A NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT
Retrieved on:
Donnerstag, August 17, 2023
Foam, COPD, Science, Science Based Targets initiative, Partnership, Inhalation, Climate, Holmes Chapel, Aerosol, Sustainability reporting, Industrial production in Shōwa Japan, HFO, VOC, Carbon, Targets, GWP, Chronic obstructive pulmonary disease, Isocyanate, Solvent, CDMO, Atmosphere of Earth, Patient, HFA, Research Triangle Park, ESG, Social, Jet fuel, Pharmaceutical industry, Renewable energy, Recipharm, Honeywell, Environment, Research
MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.
Key Points:
- MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.
- Honeywell Solstice® Air (HFO-1234ze(E) cGMP) is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs that has 99.9% less global warming potential than HFAs.
- In addition, Honeywell Solstice Air is non-flammable, non-ozone-depleting and volatile organic compound (VOC)-exempt under federal and state guidelines.
- The partnership with Honeywell follows Recipharm's announcement that it is expanding its pMDI product development and manufacturing capabilities to accommodate increased demand from pharmaceutical companies.